Starpharma Holdings Ltd - Company Profile
Powered by 
All the sales intelligence you need on Starpharma Holdings Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Starpharma Holdings Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Starpharma Holdings Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Starpharma Holdings Ltd (Starpharma) is a biotechnology company. It is advancing dendrimer technology to develop innovative therapeutics, particularly targeting serious conditions like cancer. The company’s proprietary dendrimer-based platform, DEP (Dendrimer Enhanced Product), enhances drug delivery by improving solubility, stability, bioavailability, and reducing toxicity. The technology enables targeted drug delivery to specific sites, such as tumors, optimizing therapeutic effects while minimizing side effects. The company’s product portfolio includes antimicrobial products based on its dendrimer SPL7013, such as Viraleze nasal spray, VivaGel BV, and VivaGel condom, which provide antiviral protection. Its clinical-stage oncology pipeline includes DEP SN38, DEP cabazitaxel, and DEP docetaxel. Starpharma is headquartered in Abbotsford, Victoria, Australia.
Headquarters
Australia
Address
4-6 Southampton Crescent, Abbotsford, Melbourne, Victoria, 3067
Website
www.starpharma.com
Telephone
61 3 85322700
No of Employees
50
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SPL (ASX)
Revenue (2025)
$3.9M
-40%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-22.4%
(2025 vs 2024)
Market Cap*
$218.3M
Net Profit Margin (2025)
XYZ
-104.1%
(2025 vs 2024)
* As of and is in US$
Starpharma Holdings Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Anti-Infective | VivaGel |
| Nasal Spray | DEP |
| Non-Antibiotic Gel | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Starpharma Holdings Ltd | Cyclopharm Ltd | Mesoblast Ltd | ImpediMed Ltd | Rhinomed Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Australia | Australia | Australia | Australia |
| City | Melbourne | Sydney | Melbourne | Brisbane | Cremorne |
| State/Province | Victoria | New South Wales | Victoria | Queensland | Victoria |
| No. of Employees | 50 | 95 | 81 | 77 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Cheryl Maley | Chief Executive Officer; Managing Director | Executive Board | 2024 | - |
| Justin Cahill | Chief Operating Officer; Chief Financial Officer; Secretary | Senior Management | 2025 | - |
| Jeremy Paull, Ph.D. | Chief Scientific and Regulatory Officer | Senior Management | 2025 | - |
| Robert B. Thomas | Chairman | Non Executive Board | 2014 | - |
| Tony Eglezos, Ph.D. | Vice President - Business Development | Senior Management | 2013 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer